Mirai Bio Expands LNP Delivery Into Adipocyte Tissue
CAMBRIDGE, Mass., May 14, 2026 Mirai Bio presented new preclinical data at the American Society of Gene and Cell...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
CAMBRIDGE, Mass., May 14, 2026 Mirai Bio presented new preclinical data at the American Society of Gene and Cell...
CAMBRIDGE, Mass., April 27, 2026 Mirai Bio announced it will unveil two next-generation programs focused on targeted nucleic acid...
